Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
- 388 Downloads
Background Estrogen receptor (ER) and progesterone receptor (PgR) protein expression carry weak prognostic and moderate predictive utility for the outcome of early breast cancer patients on adjuvant chemohormonotherapy. We sought to study the predictive significance and correlations of transcriptional profiling of the ER, PgR and microtubule-associated protein Tau (MAP-Tau) genes in early breast cancer. Materials and methods Messenger RNA (mRNA) was extracted from 279 formalin-fixed paraffin-embedded breast carcinomas (T1-3N0-1M0) of patients enrolled in the Hellenic Cooperative Oncology Group (HeCOG) trial HE 10/97, evaluating epirubicin-alkylator based adjuvant chemotherapy with or without paclitaxel (E-T-CMF versus E-CMF). Kinetic reverse transcription polymerase chain reaction (kRT-PCR) was applied for assessment of the expression of estrogen receptor, progesterone receptor and MAP-Tau genes in 274 evaluable patients. Cohort-based cut-offs were defined at the 25th percentile mRNA value for ER and PgR and the median for MAP-Tau. Results Two hundred and ten patients (77%) were ER and/or PgR-positive by immunohistochemistry (IHC). Positive ER and MAP-Tau mRNA status was significantly associated with administration of hormonal therapy and low grade, while MAP-Tau mRNA status correlated with premenopausal patient status. MAP-Tau strongly correlated with ER and PgR mRNA status (Spearmann r = 0.52 and 0.64, P < 0.001). The observed chance corrected agreement between determination of hormonal receptor status by kRT-PCR and IHC was moderate (Kappa = 0.41) for ER and fair (Kappa = 0.33) for PgR. At a median follow-up of 8 years, univariate analysis adjusted for treatment showed positive ER mRNA status to be of borderline significance for reduced risk of relapse (HR = 0.65, 95% CI 0.41–1.01, P = 0.055) and death (HR = 0.62, 95% CI 0.36–1.05, P = 0.077), while positive MAP-Tau mRNA status was significantly associated with reduced risk of relapse (HR = 0.50, 95% CI 0.32–0.78, P = 0.002) and death (HR = 0.49, 95% CI 0.29–0.83, P = 0.008). In multivariate analysis, only axillary nodal metastases (HR = 2.33, 95% CI 1.05–5.16, P = 0.04) and MAP-Tau mRNA status (HR = 0.46, 95% CI 0.25–0.85, P = 0.01) independently predicted patient outcome. However, MAP-Tau mRNA levels did not predict enhanced benefit from inclusion of paclitaxel in the adjuvant chemotherapy regimen (test for interaction P = 0.99). No correlation was evident between increasing ER and PgR mRNA transcription and increasing benefit from endocrine therapy in 203 ER and/or PgR IHC-positive patients receiving adjuvant hormone therapy (Wald P = 0.54 for ER, 0.51 for PR). Conclusions ER gene transcription carries weak predictive significance for benefit from endocrine therapy or for outcome, with no apparent dose-response association. The predictive significance is possibly exerted via MAP-Tau gene expression, an ER-inducible tubulin modulator with strong predictive significance for patient outcome. However, MAP-Tau mRNA did not predict benefit from the addition of a taxane to adjuvant chemotherapy. Further study of the biologic function and utility of MAP-Tau for individualising adjuvant therapy is warranted.
KeywordsEstrogen receptor Progesterone receptor Microtubule MAP-Tau Predictive value Breast cancer
The authors wish to thank all HeCOG study coordinators for data collection, Ms. E. Fragou and Ms. D. Katsala for study monitoring, Ms. Th. Spinari for tissue sample collection and Ms. M. Moschoni for data management. Supported by HeCOG research grant HE R 10/97.
- 11.Bianchini G, Zambetti M, Pusztai L et al (2007) Use of estrogen receptor expression by quantitative RT-PCR to identify an ER-negative subgroup by IHC who might benefit from hormonal therapy. 2007 Breast Cancer Symposium; Abstract 106Google Scholar
- 12.Badve SS, Baehner FL, Gray R et al (2007) ER and PR assessment in ECOG 2197: comparison of locally determined IHC with centrally determined IHC and quantitative RT-PCR. 2007 Breast Cancer Symposium; Abstract 87Google Scholar
- 15.Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E et al (2005) Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomised phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 16:1762–1771PubMedCrossRefGoogle Scholar
- 17.Hudis TL et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127–2132Google Scholar
- 23.Van Maldegem F, De Wit M, Morsink F, Musler A, Weegenaar J et al (2008) Effects of processing delay, formalin fixation and immunohistochemistry on RNA recovery from formalin-fixed paraffin-embedded tissue sections. Diagn Mol Pathol Jan 28 (Epub ahead of print)Google Scholar
- 24.Pusztai L, Ayers M, Stec J, Clark E, Hess K et al (2003) Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumours. Clin Cancer Res 9:2406–2415PubMedGoogle Scholar
- 26.Symmans WF, Sotiriou C, Anderson SK et al (2005) Measurements of estrogen receptor and reporter genes from microarrays determine receptor status and time to recurrence following adjuvant tamoxifen therapy. Breast Cancer Res Treat 94(suppl 1):308aGoogle Scholar
- 36.Rody A, Karn T, Gatje R, Ahr A, Solbach C et al (2007) Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumour response. Breast 16:86–93PubMedCrossRefGoogle Scholar